Atossa Therapeutics (ATOS) Net Cash Flow (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Net Cash Flow of -$9.6 million for Q1 2026, down 60.86% year-over-year from -$24.5 million in Q1 2025, and up 9.49% quarter-over-quarter from -$10.6 million in Q4 2025.
Atossa Therapeutics (ATOS) Net Cash Flow (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Net Cash Flow for 16 consecutive years, with -$9.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 60.86% year-over-year to -$9.6 million; the TTM figure through Mar 2026 stood at -$33.5 million (down 77.54% YoY), while the FY2025 annual figure was -$29.8 million, down 71.63% from the prior year.
- Net Cash Flow improved to -$9.6 million in Q1 2026 per ATOS's latest filing, from -$10.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at -$3.7 million in Q4 2024 and bottomed at -$10.6 million in Q4 2025.
- Historically, Net Cash Flow has averaged -$6.2 million across 5 years, with a median of -$5.9 million in 2022.
- Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 239.3% — and 2024, when it soared 35.92%.
- Atossa Therapeutics' Net Cash Flow stood at -$6.5 million in 2022, then increased by 14.7% to -$5.6 million in 2023, then surged by 33.91% to -$3.7 million in 2024, then sank by 188.08% to -$10.6 million in 2025, then grew by 9.49% to -$9.6 million in 2026.
- Business Quant data shows ATOS's Net Cash Flow at -$9.6 million in Q1 2026, -$10.6 million in Q4 2025, and -$6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 225.59 Mn |
| 10 | Atossa Therapeutics | 23.07 Mn | 23.07 Mn | - | -5.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.61 Mn |
| Jun 30, 2026 | -5.61 Mn |
| Mar 31, 2026 | -9.60 Mn |
| Mar 31, 2026 | -9.60 Mn |
| Dec 31, 2025 | -10.61 Mn |
| Dec 31, 2025 | -10.61 Mn |
| Sep 30, 2025 | -6.01 Mn |
| Sep 30, 2025 | -6.01 Mn |
| Jun 30, 2025 | -7.24 Mn |
| Jun 30, 2025 | -7.24 Mn |
| Mar 31, 2025 | -5.97 Mn |
| Mar 31, 2025 | -5.97 Mn |
| Dec 31, 2024 | -3.68 Mn |
| Dec 31, 2024 | -3.68 Mn |
| Sep 30, 2024 | -4.76 Mn |
| Sep 30, 2024 | -4.76 Mn |
| Jun 30, 2024 | -4.43 Mn |
| Jun 30, 2024 | -4.43 Mn |
| Mar 31, 2024 | -4.50 Mn |
| Mar 31, 2024 | -4.50 Mn |